Skip to main content

Table 1 Distribution of cohort characteristics, overall and between treatment allocations

From: Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT

  Placebo n = 16 (47.1%) Treatment n = 18 (52.9%)
Total infections during the study 54 44
Infection type   
  Respiratory tract infection 32 (59.3) 36 (81.8)
  Gastrointestinal infection 11 (20.4) 5 (11.4)
  Urinary tract infection 0 0
  Skin infection 2 (3.7) 0
  Ear infection 1 (1.9) 0
  Eye infection 0 1 (2.3)
  Cold sore 5 (9.3) 2 (4.6)
  Systemic/nonspecific 3 (5.6) 0
Sex   
  Male 5 (31.3) 9 (50.0)
  Female 11 (68.8) 9 (50.0)
Birthplace   
  Australia 15 (88.2) 14 (82.4)
  New Zealand 1 (5.9) 1 (5.9)
  United Kingdom 0 2 (11.8)
  Singapore 1 (5.9) 0
BMI at baseline   
  < 18.5 1 (6.3) 0
  18.5–24.9 8 (50.0) 10 (55.6)
  25.0–29.9 6 (37.5) 7 (38.9)
  30 or greater 1 (6.3) 1 (5.6)
Taking any medications at baseline?   
  No 9 (56.3) 9 (50.0)
  Yes 7 (43.8) 9 (50.0)
Taking any supplements at baseline?   
  No 12 (75.0) 15 (83.3)
  Yes 4 (25.0) 3 (16.7)
Ever smoked?   
  No 12 (75.0) 15 (83.3)
  Yes 4 (25.0) 3 (16.7)
How much time do you usually spend in the sun on weekends and holidays in summer?   
  < 30 min/day 1 (6.3) 1 (5.6)
  30–60 min/day 2 (12.5) 3 (16.7)
  1–2 h/day 6 (37.5) 4 (22.2)
  2–3 h/day 5 (31.3) 4 (22.2)
  3–4 h/day 2 (12.5) 4 (22.2)
  4 or more hours/day 0 2 (11.1)
Age 35.0 (12.5; 19–51) 30.3 (11.8; 18–52)
Baseline 25(OH)D (nmol/L) 76.4 (27.3; 36–132) 60.5 (13.9; 32–78)
  1. Results for categorical and dichotomous variables are presented at n (%). Results for age and baseline 25(OH)D are presented as mean (SD; range). Significance of difference in dichotomous or categorical variables between treatment arms is assessed by chi-square test. Significance of difference in continuous variables between treatment arms is assessed by Kruskal-Wallis test.
  2. 25(OH)D 25-hydroxyvitamin D, nmol/L nanomoles per litre.